Is vitreous humour useful for the interpretation of 3,4-methylenedioxymethamphetamine (MDMA) blood levels? Experimental approach with rabbits

被引:35
作者
De Letter, EA
De Paepe, P
Clauwaert, KM
Belpaire, FM
Lambert, WE
Van Bocxlaer, JF
Piette, MHA
机构
[1] State Univ Ghent, Dept Forens Med, B-9000 Ghent, Belgium
[2] State Univ Ghent, Heymans Inst Pharmacol, B-9000 Ghent, Belgium
[3] State Univ Ghent, Dept Toxicol, B-9000 Ghent, Belgium
关键词
3,4-methylenedioxymethamphetamine; MDMA; vitreous humour; pharmacokinetics; post-mortem stability; rabbits;
D O I
10.1007/s004140000135
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
As drug instability and redistribution are factors known to affect the interpretation of post-mortem blood levels, we questioned whether post-mortem vitreous humour concentrations could be useful as predictors for the MDMA load at the time of death. In a first series of in vivo experiments using rabbits, 3,4-methylenedioxymethamphetamine (MDMA) concentrations in plasma, blood and vitreous humour were studied as a function of time after intravenous (iv) administration of MDMA. Equilibration between the vascular compartment and vitreous humour was attained about 1 h after iv MDMA administration. In a second series of experiments, the postmortem stability of MDMA in vitreous humour in relation to ambient temperature was investigated. Post-mortem MDMA concentrations in vitreous humour were closer to the ante-mortem blood levels when compared to cardiac blood samples. These preliminary investigations in the rabbit model indicate that measurements of vitreous humour concentrations could also be of interest for predicting the blood concentration at the time of death in humans.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 50 条
[21]   3,4-Methylenedioxymethamphetamine's (MDMA's) Impact on Posttraumatic Stress Disorder [J].
White, C. Michael .
ANNALS OF PHARMACOTHERAPY, 2014, 48 (07) :908-915
[22]   Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat [J].
Upreti, Vijay V. ;
Eddington, Natalie D. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (04) :1593-1605
[23]   3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy: what the pharmacist needs to know [J].
Gallo, Alexander T. ;
Fitzgerald, Paul B. .
JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2024, 54 (03) :199-208
[24]   Age Differences in (±) 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Conditioned Taste Aversions and Monoaminergic Levels [J].
Cobuzzi, Jennifer L. ;
Siletti, Kayla A. ;
Hurwitz, Zachary E. ;
Wetzell, Bradley ;
Baumann, Michael H. ;
Riley, Anthony L. .
DEVELOPMENTAL PSYCHOBIOLOGY, 2014, 56 (04) :635-646
[25]   Demographic and health characteristics of 3,4-methylenedioxymethamphetamine users (MDMA, ecstasy) [J].
Wieckiewicz, Gniewko ;
Danel, Dariusz ;
Piegza, Magdalena ;
Gorczyca, Piotr ;
Pudlo, Robert .
PSYCHIATRIA POLSKA, 2022, 56 (05) :1109-1130
[26]   The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) [J].
Cole, JC ;
Sumnall, HR .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2003, 27 (03) :199-217
[27]   Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA; ''Ecstasy'') [J].
Cohen, RS ;
Cocores, J .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1997, 21 (04) :727-734
[28]   PERSISTENT EFFECTS OF (+/-)3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA, ECSTASY) ON HUMAN SLEEP [J].
ALLEN, RP ;
MCCANN, UD ;
RICAURTE, GA .
SLEEP, 1993, 16 (06) :560-564
[29]   ACUTE EFFECTS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ON MONOAMINES IN RAT CAUDATE [J].
GOUGH, B ;
ALI, SF ;
SLIKKER, W ;
HOLSON, RR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 39 (03) :619-623
[30]   BEHAVIORAL AND DEVELOPMENTAL EFFECTS OF 2 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) DERIVATIVES [J].
BRONSON, ME ;
BARRIOSZAMBRANO, L ;
JIANG, WW ;
CLARK, CR ;
DERUITER, J ;
NEWLAND, MC .
DRUG AND ALCOHOL DEPENDENCE, 1994, 36 (03) :161-166